Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2022)
31 slides from Cyclopharm's shareholder meeting presentation, May 17, 2022
Slide 1: Cyclopharm 2022 Annual General Meeting
For personal use only CYCLOPHARM 2022 Annual General Meeting 17 May 2022 1
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources For personal use only that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm
Slide 3: Welcome
For personal use only Welcome Mr David Heaney 3
Slide 4: Chairman's Address
For personal use only CHAIRMAN’S ADDRESS Mr David Heaney 4
Slide 5: A World Leading Diagnostic Imaging Company
A World Leading Diagnostic Imaging Company For personal use only 1 Recovery in FY 2021 from initial COVID-19 impact in primary country markets with record sales of $17.7m Continued profitability and positive cash 2 flow from sales of Technegas across 60 countries with additional revenues growing fro
Slide 6: Managing Director's Address
For personal use only MANAGING DIRECTOR’S ADDRESS Mr James McBrayer 6
Slide 7: Financial Highlights
For personal use only Sales Revenue Record Group Sales revenue of $17.7m, up 20.6% Third Party Distribution $4.1 million of new third‐party distribution revenue, up 89% Net Loss Before Tax $4.3 million loss (includes $1.3m from USFDA expenses) 2021 R&D Tax Incentive $2.3 million received in Jan 2022
Slide 8: 2021 Operating Highlights
Sales Revenue Record Group Sales revenue of $17.7m, up 20.6% with $4.1 million of For personal use only new third‐party distribution revenue USFDA Investment in the final stages of the USFDA regulatory approval 2021 US Commercialisation Preparations for subsequent rapid commercialization in the Unit
Slide 9: Building for Growth
BUILDING FOR GROWTH Technegas® is a global market leader with significant growth potential in the USA For personal use only market • Total global sales of over $93.1m AUD from 2015 to 2021 ($17.7 in FY 2021) • Technegas® currently available in over 60 countries • Over 4,400,000 patient procedures pe
Slide 10: America Coming To
For personal use only 10 AMERICA COMING TO
Slide 11: USFDA Update
1 Pre-Approval Inspection (PAI) conducted 30 March to 7 April 2021 • Inspection based on Drug-Device Combination Product For personal use only • Currently providing USDFDA updates every 60 Days • Significant Documentation Development and Revisions accomplished to date • Facility Modifications – Work
Slide 12: USA Update: Building the Fleet
For personal use only USA UPDATE Building The Fleet 200 Technegas Generators Being Built for Market Launch 12
Slide 13: Immediate Market Opportunity
600K Nuclear Medicine Ventilation 15%/600k Procedures p.a. For personal use only • The Company estimates 4,000,000 patient procedures are conducted in the USA per annum to diagnose pulmonary embolism (15% Nuclear Medicine – 85% CTPA) • 600,000 Nuclear Medicine Ventilation procedures equals $90m USD
Slide 14: USA Demand Established
USA Demand Established No requirement for large sales team due to pre-approval demand For personal use only 1 9 sites in the US already have generators installed from clinical trials 2 Multiple letters from leading clinicians, front-line workers and the SNMMI have petitioned the USFDA for the approv
Slide 15: USA Pricing & Business Model
USA Pricing & Business Model For personal use only Generators are to be placed at no cost removing potential 1 CAPEX roadblocks 2 Once off installation and training fee charged 3 Ongoing annual fee attributed to preventative maintenance, training and product support Business model expected to result
Slide 16: Expanding Indications
For personal use only EXPANDING INDICATIONS 16
Slide 17: Beyond PE applications of V/Q SPECT(/CT)
Beyond PE applications of V/Q SPECT(/CT) For personal use only Diagnosis and Preoperative Preoperative Planning radiation Advanced approach Diagnosis and follow-up of assessment of assessment of therapy to target to phenotyping monitoring of Pulmonary homogeneous lung resection tumors while chronic
Slide 18: Beyond Pulmonary Embolism Initiatives Underway
Beyond Pulmonary Embolism Initiatives Underway 392 Patients enrolled globally across 6 Cyclopharm sponsored Beyond PE clinical trials For personal use only 1 Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response to therapy in severe asthma and COPD1 100 Patient Study * 100% Recru
Slide 19: Three Value Horizons
THREE VALUE HORIZONS For personal use only Horizon 2* 3 to 8 Years Horizon 3 >8 Years ENTERPRISE VALUE Convert CTPA Horizon 1* Double existing Nuc Med Innovate Beyond PE 0 to 5 Years Procedures for PE HALF BILLION Establish USA combined sufferers of Asthma 80% Conversion of the total and Chronic Obs
Slide 20: Key Catalysts for the Next Years
KEY Catalysts for the Next 2 Years For personal use only 1 FDA approval for Technegas expected mid 2023 2 First sales in US announce (shortly after approval) 3 Ongoing updates on No. Generators placed in US Clinical proof of concept & validation in new substantive respiratory 4 indications 20
Slide 21: Cyclopharm Investment Case
CYCLOPHARM INVESTMENT CASE For personal use only Profitable and First in Class Recurring Revenue USFDA Approval Technegas Product Growing MedTech Established Gold Standard From single patient Set to quadruple the size expansion Underlying business Proprietary product sales to consumables of the exis
Slide 22: Business Q&A
For personal use only 22 Business Q&A
Slide 23: Formal Business
For personal use only FORMAL BUSINESS Mr David Heaney 23
Slide 24: Online Attendees – Registration Process & Voting
Online Attendees – Registration Process & Voting For personal use only 1 2 3 Go to Once logged in you will see that Click on “register” to register https://investor.automic.com.au/ the meeting is open for your attendance for the meeting #/home registration. Click on “view”
Slide 25: Online Attendees – Question Process & Voting
Online Attendees – Registration Process Question Process & & Voting Voting For personal use only TBC 4 5 6 Once the Chair of the Meeting To vote simply select the Once voting is declared closed declares voting open, you direction in which you would like you must select “next” and then should select
Slide 26: 2022 AGM – Formal Business
2022 AGM – Formal Business For personal use only (a) Financial Statements !1 (b) Remuneration Report !2 Election of Ms Dianne Angus as Director 26
Slide 27: CYC AGM 2022 Resolutions
CYC AGM 2022 Resolutions For personal use only 1 That the Remuneration Report as set out in the Annual Report of the Company for the financial year ended 31 December 2021 be adopted. Resolution For Against Discretionary Abstain 1(b) Remuneration Report 49,395,573 56,376 14,320,270 14,597 Questions?
Slide 28: CYC AGM 2022 Resolutions
CYC AGM 2022 Resolutions For personal use only 2 That Ms Dianne Angus, being eligible and having consented to act, be elected as a Director of the Company. Resolution For Against Discretionary Abstain 2 Election of Ms Dianne Angus as Director 51,527,799 19,074 14,847,931 7,174 Questions? 28
Slide 29: Summary of proxies received at closing date
2022 AGM – Summary of proxies received at closing date For personal use only Resolution For Against Discretionary Abstain 1(b) Remuneration Report 49,395,573 56,376 14,320,270 14,597 2 Election of Ms Dianne Angus 51,527,799 19,074 14,847,931 7,174 as Director 29
Slide 30: Votes are Being Tabulated
Technegas: World’s Best Functional Lung For personal use only Ventilation Imaging Agent Votes are Being Tabulated 30
Slide 31: Thank You
For personal use only T H A N K YO U 31